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Abstract
Background: Gastrointestinal bleeding is a common problem and its most common etiology is
peptic ulcer disease. Ulcer rebleeding is considered a perilous complication for patients. To reduce
the rate of rebleeding and to fasten the improvement of patients' general conditions, most
emergency departments in Iran use H2-blockers before endoscopic procedures (i.e. intravenous
omeprazole is not available in Iran). The aim of this study was to compare therapeutic effects of
oral omeprazole and intravenous cimetidine on reducing rebleeding rates, duration of
hospitalization, and the need for blood transfusion in duodenal ulcer patients.
Methods: In this clinical trial, 80 patients with upper gastrointestinal bleeding due to duodenal
peptic ulcer and endoscopic evidence of rebleeding referring to emergency departments of Imam
and Sina hospitals in Tabriz, Iran were randomly assigned to two equal groups; one was treated
with intravenous cimetidine 800 mg per day and the other, with 40 mg oral omeprazole per day.
Results: No statistically significant difference was found between cimetidine and omeprazole
groups in regards to sex, age, alcohol consumption, cigarette smoking, NSAID consumption,
endoscopic evidence of rebleeding, mean hemoglobin and mean BUN levels on admission, duration
of hospitalization and the mean time of rebleeding. However, the need for blood transfusion was
much lower in omeprazole than in cimetidine group (mean: 1.68 versus 3.58 units, respectively; p
< 0.003). Moreover, rebleeding rate was significantly lower in omeprazole group (15%) than in
cimetidine group (50%) (p < 0.001).
Conclusion:  This study demonstrated that oral omeprazole significantly excels intravenous
cimetidine in reducing the need for blood transfusion and lowering rebleeding rates in patients with
upper gastrointestinal bleeding. Though not statistically significant (p = 0.074), shorter periods of
hospitalization were found for omeprazole group which merits consideration for cost minimization.
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Background
Gastrointestinal bleeding is a common problem in gastro-
enterology and its most common etiology is peptic ulcer
disease which accounts for 50% of the cases with gastroin-
testinal bleeding [1]. In the majority of the cases, bleeding
ceases spontaneously [2]. However, some factors may
contribute to continuous bleeding and rebleeding which
may aggravate prognosis. The risk factors for continuous
bleeding or rebleeding include age over 60 years, gastric
ulcer, severity of the first episode of bleeding, rebleeding
in hospital, persistent or recurrent bleeding, and underly-
ing diseases such as hypertension, chronic obstructive pul-
monary disease, diabetes mellitus, recent myocardial
infarction, cerebrovascular accidents and renal failure [3].
Some endoscopic findings, the so-called endoscopic evi-
dence of rebleeding risk, can increase the risk of rebleed-
ing up to 10% to 30% in peptic ulcer patients [4-6].
Endoscopic treatment of ulcers with higher risk of bleed-
ing can decrease the rate of rebleeding, associated compli-
cations and even mortality [7-9]. H2-receptor blockers
and proton pump inhibitors have been extensively used
in the treatment of peptic ulcers. Omeprazole, a proton
pump inhibitor, prevents rebleeding by increasing gastric
pH and stabilizing blood clots in the base of the ulcer.
Nevertheless, in several studies, H2-receptor blockers were
not found to have any strict and persistent effect on gas-
trointestinal bleeding and did not decrease the rates of
rebleeding, surgical interventions or mortality [6,10,11].
The role of treatment with proton pump inhibitors in the
patients with active or recent ulcer bleeding is controver-
sial. If given in an adequate dose by continuous intrave-
nous infusion, proton pump inhibitors can maintain
intragastric pH at 6 or above. At such levels of pH, peptic
activity is minimized, platelet function is optimized, and
fibrinolysis is inhibited; these effects may help to stabilize
clot formation in an ulcer.
In case intravenous treatment is unavailable or particu-
larly expensive, oral treatment would be appropriate. Fur-
thermore, it would be less costly for any patient with
recent ulcer bleeding who did not require endoscopic hae-
mostatic therapy. One systematic review and meta-analy-
sis found that proton pump inhibitors reduce the risk of
ulcer rebleeding but does not influence overall mortality
from ulcer bleeding [12].
Considering the absence of intravenous proton pump
inhibitors in the conventional pharmacopoeia of Iran,
intravenous cimetidine 200 mg is used every six hours
before performing an upper gastrointestinal endoscopy
for treating upper gastrointestinal bleeding in emergency
departments in the majority of medical care centers in the
country. It is also noteworthy that intravenous cimetidine
is more available than intravenous ranitidine in Iran. The
aim of this study was to compare the therapeutic effects of
oral omeprazole and intravenous cimetidine (immedi-
ately started in the emergency department) on decreasing
rebleeding rates, duration of hospitalization and the need
for blood transfusion. We also tried to adhere to CON-
SORT statement http://www.consort-statement.org in
reporting this clinical trial.
Methods
All of the patients over 12 years of age with upper gas-
trointestinal bleeding (hematemesis and/or melena)
referring to emergency departments of Imam and Sina
hospitals in Tabriz, Iran were assessed for inclusion crite-
ria of the study. The patients with gastrointestinal bleed-
ing due to duodenal ulcer and endoscopic risk factors for
rebleeding were candidates for inclusion in the study.
Endoscopic risk factors for ulcer rebleeding were hematin-
covered flat spots, sentinel clot, visible vessels, arterial
oozing bleeding, and arterial spurting bleeding. Exclusion
criteria were gastrointestinal bleeding not caused by duo-
denal ulcer, bleeding caused by drugs (e.g. anticoagu-
lants) except NSAIDS or underlying diseases (e.g.
thrombocytopenia and coagulopathies), and absence of
endoscopic risk factors of rebleeding. A computerized ran-
dom-number generator was used to produce the random
allocation sequence on an equal basis (probability of
receiving each treatment was set to be 50% before assign-
ment). Concealment of allocation was performed using
sequentially numbered, sealed, opaque envelopes. A writ-
ten informed consent was obtained from each patient
before allocation.
All of the patients with upper gastrointestinal bleeding
were treated with intravenous cimetidine (Darou-Pakhsh,
Iran) 200 mg every 6 hours and underwent upper gas-
trointestinal endoscopy within 12 to 24 hours of hemody-
namic stabilization and gastric lavage. In cases with
hemodynamic instability or continuous bleeding, endos-
copy was performed on an emergency basis and those
with endoscopic risk factors for rebleeding were treated
with alcohol (50% solution) and adrenaline (1/10000
solution). Thermal coagulation was not used because it
was not available in our center.
Patients meeting inclusion criteria were randomly
assigned (as explained above) to two groups of equal
number. One group was treated with continuous intrave-
nous cimetidine (Darou-Pakhsh, Iran) 200 mg every six
hours for 3 days followed by oral cimetidine (Darou-
Pakhsh, Iran) 400 mg every 12 hours to the 14th day after
admission. In the other group, intravenous cimetidine
was discontinued and omeprazole suspension (the con-
tents of one 20-mg omeprazole capsule [Exir, Iran] in 50
ml of normal saline) was prescribed orally every 12 hoursBMC Gastroenterology 2006, 6:2 http://www.biomedcentral.com/1471-230X/6/2
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CONSORT flow chart of the clinical trial comparing oral omeprazole and intravenous cimetidine in reducing complications of  duodenal peptic ulcer in 80 Iranian patients Figure 1
CONSORT flow chart of the clinical trial comparing oral omeprazole and intravenous cimetidine in reducing complications of 
duodenal peptic ulcer in 80 Iranian patients.BMC Gastroenterology 2006, 6:2 http://www.biomedcentral.com/1471-230X/6/2
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for 3 days and then was replaced by oral omeprazole 20-
mg capsules every 12 hours to the 14th day after admis-
sion. Omeprazole administration in form of suspension
was because the patients in emergency department had an
NG-tube and could not take omeprazole capsules early in
hospitalization. Patients were kept blind to the two inter-
vention modes however it was not possible to keep health
care providers blind to interventions since the form of
administered drugs (oral cimetidine tablets and omepra-
zole suspension) was apparently distinguishable early in
treatment.
Active bleeding was defined as observation of bright-red
blood on a gastric lavage. The duration of active bleeding
was defined as the period of time between the first and the
last gastric lavage showing bright-red blood on the fre-
quent lavages routinely performed as standard treatment
for patients with upper gastrointestinal bleeding in the
emergency department. Rebleeding was defined as obser-
vation of red blood in the stomach, a drop of serum
hemoglobin more than 2 gr/dl during 24 hours, continu-
ous melena for more than 7 days, or instability of vital
signs (defined as a pulse rate more than 110 per minute,
positive tilt sign, or a drop of systolic blood pressure
below 90 mmHg in supine position).
In the cases with rebleeding; the time interval from pri-
mary bleeding, number of rebleeding periods, and meth-
ods of treatment were recorded. The results were analyzed
with SPSS software version 11.5 using chi-square and t
tests. P values less than 0.05 were regarded statistically sig-
nificant.
Results
Of 128 patients with upper gastrointestinal bleeding
(hematemesis or melena) referring to emergency depart-
ments of Imam and Sina hospitals in Tabriz, 80 met the
inclusion criteria of the study. Figure 1 shows the CON-
SORT diagram showing flow of cases in this clinical trial.
The mean age (± SD) of all patients was 51.53 (± 18.1)
years. The mean age was 53.5 and 49.5 years for cimeti-
dine and omeprazole groups, respectively. Statistical anal-
ysis interestingly showed that case and control groups
were matched for sex (p = 0.639) and age (p = 0.332).
There was no statistically significant difference between
cimetidine and omeprazole groups in regards to sex, age,
alcohol consumption, cigarette smoking, NSAID con-
sumption, endoscopic risk factors for rebleeding, mean
hemoglobin or mean BUN levels on admission, duration
of hospitalization and mean time of rebleeding (Tables 1
and 2). It is noteworthy that though age and sex matching
was not aimed from the start of the study, the case and
Table 1: The characteristics of 80 patients with upper gastrointestinal bleeding treated with intravenous cimetidine or oral 
omeprazole.
Cimetidine group No (%) Omeprazole group No (%) p values
Hx of alcohol 4 (10) 7 (17.5) 0.33
Hx of cigarette smoking 14 (35) 15 (37.5) 0.816
Hx of NSAIDs 19 (47.5) 18 (45) 0.823
Hx of epigastric pain 22 (55) 21 (52.5) 0.823
Pre-existing disease 18 (45) 17 (42.5) 0.283
Hx of gastrointestinal bleeding 3 (7.5) 10 (25) 0.034
Mean Hb level (gr/dl) 9.53 10.04 0.392
Mean BUN (mg/dl) 16.55 10.72 0.629
Blood transfusion (units) 3.58 1.68 0.003
Mean interval of rebleeding (days) 2.1 2.8 0.34
Rebleeding 20 (50) 6 (15) 0.001
Duration of hospitalization (days) 7.46 5.6 0.074
Mortality 3 (7.5) 1 (2.5) 0.24
Hx: History
Table 2: The frequency of endoscopic findings according to Forrest classification in 80 patients with upper gastrointestinal bleeding 
treated with intravenous cimetidine or oral omeprazole. P values for all classes were 0.9.
Endoscopic findings Cimetidine group No (%) Omeprazole group No (%)
Arterial spurting bleeding (IA) 3 (7.5) 2 (5)
Arterial oozing bleeding (IB) 15 (37.5) 13 (32.5)
Visible vessel (IIA) 5 (12.5) 3 (7.5)
Sentinel clot (IIB) 12 (30) 15 (37.5)
Hematin covered flat spot (IIC) 5 (12.5) 7 (17.5)BMC Gastroenterology 2006, 6:2 http://www.biomedcentral.com/1471-230X/6/2
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control groups were incidentally found to be age and sex
matched at the time of statistical analysis.
The mean duration of active bleeding (see methods) was
longer in omeprazole group compared with cimetidine
group. Rebleeding rate in omeprazole group (15%) was
significantly lower than that of cimetidine group (50%)
(p < 0.001). Surgical interventions were needed for 6 cases
in cimetidine, and only 1 case in omeprazole group.
While three patients in cimetidine group died (two
because of rebleeding and one due to cerebrovascular
accident), there was only one dead case in omeprazole
group (because of pancreatic malignancy).
Discussion
Many studies have confirmed that Asian patients with
duodenal ulcer had smaller maximal acid output (MAO)
than Caucasian patients. [13] Khuroo et al also demon-
strated that the parietal cell mass in duodenal ulcers was
much lower in Indian patients than in those in Western
countries [14]. This evidence may partly justify consider-
ing using oral (versus intravenous high-dose) omeprazole
in controlling peptic ulcer bleeding in patients of this
study.
Ulcer healing time is shorter with omeprazole compared
with that with cimetidine or ranitidine [15]. Since pepsin
is activated in pH levels lower than 4 causing clot lysis
[10] and omeprazole increases gastric pH, it can stabilize
the blood clot in ulcer base and so prevents rebleeding
[16,17]. Lau et al used adrenaline injection and thermal
probe for bleeding control and omeprazole infusion for
rebleeding prevention and found a rebleeding rate of
6.7% (mortality rate: 4.2%) in omeprazole and 22.5%
(mortality rate: 10%) in placebo group [18]. Schaffalitzky
et al used intravenous omeprazole with and without ther-
mal coagulation or electrocoagulation and found the first-
72-hour improvement rate to be 94% in omeprazole, and
79.7% in placebo group. Mortality rates in their study
were 7.7% in cimetidine and 8.5% in omeprazole group
[19]. In our study, rebleeding rate was 50% in cimetidine
and 15% in oral omeprazole group which showed a statis-
tically significant difference (p = 0.001) and confirmed
the similar results from previous studies [44, [5,20]].
While the rebleeding rate in cimetidine group was 3 times
higher than that in omeprazole group in our study, Lin et
al found rebleeding rates to be 6 times higher in cimeti-
dine group [4]. Overall, 25% of our patients experienced
rebleeding in rates similar to those found by previous
studies (10% to 30%) including the study of Katschinski
(11%) [21,22]. In all cases, rebleeding occurred in
patients with endoscopic risk factors for rebleeding.
In Lin et al study, the mean duration of hospitalization
was 6 days in cimetidine and 7 days in omeprazole group
which was not significantly different (p > 0.05) [4]. Simi-
larly, the difference in duration of hospitalization
between two groups in our study was not statistically sig-
nificant (p = 0.074) though Kaviani et al found this differ-
ence to be significant (p = 0.0032) [23].
In our study, the mean amount of blood transfusion was
3.58 units for cimetidine and 1.68 units for omeprazole
group which showed a statistically significant difference
(p = 0.003); a result previously found by Lin et al (p =
0.008) [4].
Mortality in cimetidine and omeprazole groups was 2%
versus none in Lin et al study (p > 0.05)4 and 1.99% versus
1.84% in the study by Li et al (p > 0.05)13, respectively. In
our study, mortality rate was 7.5% in cimetidine and 2.5%
in omeprazole group; we similarly found no significant
difference (p = 0.24). The total mortality rate in two
groups in our study was 10% while the same figure was
8.5% in Katschinsky and 6% to 7% in Barkun et al studies
[11,21].
All death cases in our study were among the patients older
than 60 years of age. Our results were similar to Katschin-
ski's findings [21] but in conflict with the findings of Segal
et al [24]. Furthermore, the majority of death cases in our
study were among patients with underlying diseases
though rebleeding was the cause of 2 deaths in cimetidine
group. This result was different from that of Katschinski's
study [21]. There was only one death because of pancre-
atic malignancy in omeprazole group.
Conclusion
In conclusion, this study suggested that patients treated
with oral omeprazole had lower rebleeding rates (p =
0.001) and lower need for blood transfusion (p = 0.003)
compared with those treated with intravenous cimetidine.
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